Abstract: The present invention relates to a composition for preventing, treating or improving a prostate disease containing Acanthopanax sessiliflorus, Phragmites rhizome, and Pinus densiflora extracts as an active ingredient. According to the present invention, the complex extract of Acanthopanax sessiliflorus, Phragmites rhizome, and Pinus densiflora has an effect of inhibiting the activity of 5?-reductase associated with benign prostatic hyperplasia and has an advantage of having a few or no side effects of reducing a male sexual function by using a synthetic compound in the related art using ingredients derived from natural plants. Further, it is confirmed that in a complex extract obtained by mixing Acanthopanax sessiliflorus, Phragmites rhizome, and Pinus densiflora extracts at a more proper ratio, the 5?-reductase inhibitory activity is significantly excellent.

Abstract: The present invention relates to a composition for preventing, treating or improving a prostate disease containing acanthopanax sessiliflorus, phragmites rhizome, and pinus densiflora extracts as an active ingredient. According to the present invention, the complex extract of acanthopanax sessiliflorus, phragmites rhizome, and pinus densiflora has an effect of inhibiting the activity of 5?-reductase associated with benign prostatic hyperplasia and has an advantage of having a few or no side effects of reducing a male sexual function by using a synthetic compound in the related art using ingredients derived from natural plants. Further, it is confirmed that in a complex extract obtained by mixing acanthopanax sessiliflorus, phragmites rhizome, and pinus densiflora extracts at a more proper ratio, the 5?-reductase inhibitory activity is significantly excellent.

Abstract: The present invention relates to a composition for treating a bacterial infection comprising an extract from a bark of Alnus pendula, or diarylheptanoid compound as an active ingredient. The extract from a bark of Alnus pendula, diarylheptanoid compound of the present composition has a remarkably excellent anti-bacterial activity against bacteria, specifically Staphylococcus aureus. Therefore, the extract and compound of the present invention may be utilized as an active ingredient of drug, cosmetics, functional food and animal feed for treating bacterial infection, in particular an infection of S. aureus.

Abstract: The present invention relates to a composition for treating atopic dermatitis comprising hirsutenone as an active ingredient. Hirsutenone as the active ingredient of the present composition decreases the number of eosinophil and the level of IgE increased in atopic dermatitis and remarkably reduces expression amounts of immune regulatory cytokine (e.g., IL-4, IL-5 and IL-13) associated with atopic dermatitis. In addition, hirsutenone decreases COX-2 and iNOS expression. Hirsutenone as the active ingredient of the present composition could be effectively used in drugs, cosmetics and foods for treating atopic dermatitis or relieving a symptom of atopic dermatitis.

Abstract: The present invention relates to a composition for treating a bacterial infection comprising an extract from a bark of Alnus pendula, or diarylheptanoid compound as an active ingredient. The extract from a bark of Alnus pendula, diarylheptanoid compound of the present composition has a remarkably excellent anti-bacterial activity against bacteria, specifically Staphylococcus aureus. Therefore, the extract and compound of the present invention may be utilized as an active ingredient of drug, cosmetics, functional food and animal feed for treating bacterial infection, in particular an infection of S. aureus.

Abstract: The present invention relates to a composition for treating atopic dermatitis comprising hirsutenone as an active ingredient. Hirsutenone as the active ingredient of the present composition decreases the number of eosinophil and the level of IgE increased in atopic dermatitis and remarkably reduces expression amounts of immune regulatory cytokine (e.g., IL-4, IL-5 and IL-13) associated with atopic dermatitis. In addition, hirsutenone decreases COX-2 and iNOS expression. Hirsutenone as the active ingredient of the present composition could be effectively used in drugs, cosmetics and foods for treating atopic dermatitis or relieving a symptom of atopic dermatitis.

Abstract: The present invention relates to a composition for treating atopic dermatitis comprising hirsutanonol as an active ingredient. Hirsutanonol or oregonin as the active ingredient of the present composition decreases the number of eosinophil increased in atopic dermatitis and regulates expression amounts of immune regulatory cytokines, IL-4, IL-5, IL-10 and IL-13 associated with atopic dermatitis. In addition, hirsutanonol and oregonin increase MBD (mouse beta-defensin)-1, MBD-2 and MBD-3 expression and decrease COX-2 and iNOS expression in mouse animal model of atopic dermatitis. Hirsutanonol and oregonin as the active ingredient of the present composition could be effectively used in drugs, cosmetics and foods for treating atopic dermatitis.